2 1 Shi Ji Jing Ji Bao Dao·2025-12-19 02:20Group 1 - The core management team of BeiGene has undergone a significant adjustment, with Dr. Wang Lai appointed as President while retaining his role as Global Head of R&D, overseeing key functions such as R&D, business development, and alliance management [1] - Dr. Wu Xiaobin, who previously held the position of President, remains in his role as President and Chief Operating Officer, making BeiGene the first pharmaceutical company to establish a "dual president" position [1] - In August, BeiGene also experienced a major personnel change with the appointment of Sean Shan, former Senior Vice President at Takeda Pharmaceuticals, as General Manager for Greater China, Central Asia, and South Asia, reporting to Dr. Wu Xiaobin [1] Group 2 - BeiGene has shown strong growth as a leading innovative drug company, achieving total revenue of 17.518 billion yuan in the first half of the year, representing a year-on-year increase of 46.0% [2] - The net profit attributable to the parent company reached 450 million yuan, marking a turnaround from losses in the same period last year [2] - The management team is expected to drive further business upgrades, and the company will continue to provide updates on any new developments [2]